What medicines should be avoided by patients suffering from “sulfa allergy”?

12 June 2020This updated Medicines Q&A evaluates the limited evidence available on cross-sensitivity between sulfonamide-containing medicines and lists classes of medication that contain a sulfonamide in their…
Search Articles

Medicine Compliance Aid Stability

genericActavis UK Ltd

Actavis UK Ltd
Tablets 50mg, 100mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from moisture
Protect from moisture and light.
20 April 2015

Lactation Safety Information

Alternative microbiologically appropriate antibacterial
Limited published evidence of safety
Significant amounts in breast milk
Haemolytic anaemia reported in one infant
Avoid in known G6PD deficiency, hyperbilirubinaemia, and in jaundiced premature infants because of risk of kernicterus
23 September 2020

New Medicines

Aczone (US)Acne vulgaris


Aczone (US)
New formulation

Development and Regulatory status

Dec 19Launch in UK appears unlikely [7].
Sep 19Launched in the US for treatment of acne in children aged 9 to 11 years; this was based on data from a Phase IV trial (NCT02959970) [6].
Feb 16FDA announce approval of a new 7.5% concentration of dapsone (ACZONE) gel for topical treatment for acne in patients 12 years of age and older [5].


Tetrahydrofolate dehydrogenase inhibitor formulated as a topical 5% and 7.5% gel formulation of the antibacterial dapsone using Solvent-Microparticle (SMP™) delivery technology [2]
Moderate-to-severe acne affects about 20% of young people [3].
Acne vulgaris

Trial or other data

Nov 14PIII NCT01974141 & NCT01974323 complete [4].
Nov 13NCT01974141 and NCT01974323 are two PIII studies of dapsone gel vs vehicle control each in 2180 patients with acne vulgaris. The primary outcomes are % of patients with none or minimal on the 5-point Global Acne Assessment Score (GAAS) Scale and change from baseline in inflammatory and noninflammatory facial lesion counts, all at 12 weeks. The studies start Nov 13 and are due to complete May 15 [1]